AUS
NZ
UK
CA
USA
IND
Highlights
- Imugene names Dr John Byon as new Chief Medical Officer
- Dr Byon brings vast experience in cancer immunotherapy
- Clinical pipeline advancement aims to boost treatment options
Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, has announced the appointment of Dr John Byon as its new Chief Medical Officer (CMO). The move signifies a strategic step forward in advancing its promising pipeline of cancer immunotherapies. This leadership transition comes at a time when the company is striving to make a more prominent mark on the ASX200 index with its innovative treatment programs.
Dr Byon, a physician-scientist, boasts an extensive background in immunotherapy, having held key leadership roles at industry heavyweights including Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics, and Genentech. With both Doctor of Medicine and Doctor of Philosophy degrees from Tulane University and a science degree from the Massachusetts Institute of Technology, he brings a strong academic foundation paired with decades of experience in cutting-edge oncology research.
Having joined Imugene in September 2023 as Senior Vice President of Clinical Development, Dr Byon has already made a notable impact. He was instrumental in advancing a combination therapy involving Imugene’s allogeneic CAR-T therapy, azer-cel, and interleukin-2 (IL-2), which has shown encouraging early results. The combination is currently undergoing Phase 1b trials in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a difficult-to-treat form of blood cancer.
Early trial data suggests that the IL-2 integration has significantly improved both efficacy and durability, yielding complete response rates that offer renewed hope for patients unresponsive to existing treatments, including autologous CAR-T therapy.
Prior to joining Imugene, Dr Byon led a comprehensive pipeline of CAR-T and CAR-NK therapies at Fate Therapeutics (NASDAQ:FATE). His career achievements include spearheading the development of atezolizumab during his tenure at Genentech, guiding several candidates from early research to late-stage trials.
This strategic appointment comes following the departure of former CMO Dr Paul Woodard. The board has acknowledged Woodard’s contributions during his tenure and now looks ahead to a new chapter under Dr Byon’s leadership.
As Imugene intensifies efforts to deliver breakthrough cancer therapies and move closer to commercialisation, this leadership reinforcement aligns with its long-term growth ambitions. With investor interest in ASX dividend stocks rising, the biotech company’s evolving pipeline and clinical advancements could garner increasing attention from growth-focused portfolios tracking the ASX200 landscape.
